Abstract: 0bjective To evaluate the efficacy and side effects of peginterferon alfa-2a or alfa-2b（PEG-IFNα-2a/α-2b）with ribavirin for treatment of hepatitis C infection,which could be helpful for optimizing the treatment strategy and increasing clinical recovery rate of chronic hepatitis C. Methods 60 patients with chronic hepatitis C were selected and 30 patients received PEG-IFNα-2a with ribavirin therapy for 48 works（A group） and other 30 received PEG-IFNα-2b with ribavirin therapy for 48 works（B group）,and a 24-week of follow-up was performed. HCV-RNA was detected at the baseline,4-week postmanagement,12-week postmanagement,48-week postmanagement,and 24-week after completion of a full course,respectively. The rapid virological response（RVR）rate,early virological response（EVR） rate,end of treatment virological response（ETVR）rate,sustained virological response（SVR）rate,relapse rate and adverse reactions were assessed. Results The RVR,EVR,ETVR,SVR and relapse rate in A group were 46.7%,63.3%,86.7%,80.0% and 6.7%,respectively,which were similar with that in B group（40.0%,56.7%,80.0%,76.7% and 3.3%,respectively,P>0.05）. The safety profile,adverse reactions and tolerance were also similar. Serious adverse events were not observed. Conclusion The sustained virological response and tolerance on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection are similar.

Key words: Hepatitis C, Peginterferon, Therapy